Biotech 2050 Podcast cover image

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Biotech 2050 Podcast

00:00

Intro

This chapter explores the speaker's transition from practicing medicine at the Cleveland Clinic to their role in biotech at Genzyme, focusing on early gene therapy advancements for cystic fibrosis. Through personal anecdotes, they highlight the critical collaboration needed among stakeholders to enhance treatments for rare diseases.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app